CMX001 was developed as an orally active, lipophilic form of cidofovir (CDV) and has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses and orthopoxviruses.
Brincidofovir 细胞实验
Cell Line
Concentration
Treated Time
Description
References
primary mouse cortical cells
9.15 nM (IC50)
24 h
Evaluated antiviral activity of BCV against MuPyV, showing significant inhibition of virus production.
mBio. 2024 Aug 14;15(8):e0104924
primary mouse cortical cells
112 µM (CC50)
84 h
Assessed cytotoxicity of BCV, showing BCV was well-tolerated in cortical cells.
mBio. 2024 Aug 14;15(8):e0104924
primary adult mouse kidney (AMK) epithelial cells
0.515 µM
24 h
Evaluated antiviral activity of BCV against MuPyV, showing significant inhibition of virus production.
mBio. 2024 Aug 14;15(8):e0104924
primary adult mouse kidney (AMK) epithelial cells
105 µM (CC50)
84 h
Assessed cytotoxicity of BCV, showing BCV was well-tolerated in AMK cells.
mBio. 2024 Aug 14;15(8):e0104924
primary porcine alveolar macrophages
2.76 nM (IC50)
72 h
Evaluate the inhibitory effect of Brincidofovir on ASFV replication, showing significant inhibition without cytotoxicity.
Emerg Microbes Infect. 2023 Dec;12(2):2220572
Brincidofovir 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
Immune-deficient mouse model
Oral gavage
20 mg/kg
Every 48 hours for 3 doses
Brincidofovir significantly reduced viral loads and extended survival in immune-deficient mice
搜索
